Integrating Gene Therapy and TKIs with Current Second-Generation Anti-VEGF Agents in Clinical Practice

In this forward-looking segment, Dr. Harit Bhatt and Dr. Deepak Sambhara discuss the rapidly evolving next generation of retinal therapeutics, focusing on tyrosine kinase inhibitors (TKIs) and gene therapy. Dr. Sambhara anticipates being an early adopter, recognizing these innovations as potential solutions to the increasing treatment burden and capacity challenges facing retina specialists. He underscores key considerations such as cost, coverage, and patient selection, predicting that judicious, individualized use will be essential for maximizing benefit and sustainability. Dr. Bhatt echoes these sentiments, emphasizing that optional therapy pathways foster innovation and patient-centered care. Both clinicians agree that as durability becomes the defining goal of retinal disease management, emerging modalities will complement existing anti-VEGF agents—helping to meet the needs of a growing, aging patient population. The conversation closes on an optimistic note, highlighting how innovation, flexibility, and access will define the next decade in retina care.